|
|
Article: Findings from U. Hillebrand and co-researchers advance knowledge in enzyme research.
- Article from:
- Blood Weekly
- Article date:
- November 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"Whether the use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker inhibitor (ACEI/ARB) is beneficial in renal transplant recipients remains controversial. In this retrospective study on 505 renal transplant recipients, we analyzed blood pressure and graft survival according to antihypertensive treatment with ACE-I/ARB and/or calcium channel blockers (CCB) over a period of 10 years," scientists in Munster, Germany report (see also Enzyme Research).
"were stratified according to their blood pressure 1 year after transplantation [controlled (
<130/80 mmHg; CTR, 181 patients) and noncontrolled (> 130/80 mmHg; non-CTR, 324 patients)] and according to antihypertensive treatment (ACE-I/ARB and/or ...
Related newspaper, magazine, and journal articles:
|